SFE Investment Counsel lessened its stake in Becton, Dickinson and Company (NYSE:BDX) by 13.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 30,451 shares of the medical instruments supplier’s stock after selling 4,820 shares during the quarter. Becton, Dickinson and makes up approximately 2.4% of SFE Investment Counsel’s holdings, making the stock its 13th biggest holding. SFE Investment Counsel’s holdings in Becton, Dickinson and were worth $5,941,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. North Star Investment Management Corp. raised its stake in shares of Becton, Dickinson and by 3.4% in the 1st quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after purchasing an additional 18 shares in the last quarter. Almanack Investment Partners LLC. acquired a new stake in shares of Becton, Dickinson and in the 1st quarter valued at about $105,000. Parkside Financial Bank & Trust raised its stake in shares of Becton, Dickinson and by 1.4% in the 1st quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after purchasing an additional 9 shares in the last quarter. QCI Asset Management Inc. NY raised its stake in shares of Becton, Dickinson and by 9.2% in the 1st quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock valued at $130,000 after purchasing an additional 60 shares in the last quarter. Finally, Financial Architects Inc raised its stake in shares of Becton, Dickinson and by 8.0% in the 2nd quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after purchasing an additional 54 shares in the last quarter. Institutional investors and hedge funds own 87.43% of the company’s stock.

Several equities research analysts recently weighed in on the stock. BidaskClub upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Cowen and Company reiterated an “outperform” rating and set a $230.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. Barclays PLC reiterated an “equal weight” rating and set a $210.00 price objective (up previously from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective on the stock in a research note on Monday, July 17th. Finally, Raymond James Financial, Inc. upgraded shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and dropped their price objective for the stock from $210.00 to $180.00 in a research note on Friday, June 30th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $196.93.

WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/16/becton-dickinson-and-company-bdx-stake-lessened-by-sfe-investment-counsel.html.

In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,512 shares of the business’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the transaction, the insider now directly owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the business’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the transaction, the insider now directly owns 12,861 shares of the company’s stock, valued at $2,538,890.01. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 75,904 shares of company stock valued at $15,242,688. Insiders own 1.40% of the company’s stock.

Shares of Becton, Dickinson and Company (BDX) opened at 195.34 on Friday. The firm has a market cap of $44.45 billion, a price-to-earnings ratio of 56.57 and a beta of 1.06. The firm has a 50 day moving average of $199.43 and a 200 day moving average of $191.33. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $3.06 billion. During the same period last year, the firm posted $2.35 EPS. The firm’s quarterly revenue was down 5.1% on a year-over-year basis. Equities analysts predict that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be paid a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.49%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.